[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alpha Tau Medical Ltd Cl A (DRTS)

Alpha Tau Medical Ltd Cl A (DRTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,172,431
  • Shares Outstanding, K 90,326
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,630 K
  • EBIT $ -13 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 16.22

Options Overview Details

View History
  • Implied Volatility 93.04% (+1.80%)
  • Historical Volatility 92.22%
  • IV Percentile 15%
  • IV Rank 2.15%
  • IV High 812.34% on 12/09/25
  • IV Low 77.26% on 05/05/26
  • Expected Move (DTE 6) 1.11 (8.69%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 799
  • Volume Avg (30-Day) 1,151
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 24,148
  • Open Int (30-Day) 18,883
  • Expected Range 11.61 to 13.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.14
  • Number of Estimates 2
  • High Estimate $-0.14
  • Low Estimate $-0.14
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.21 +38.00%
on 06/16/26
14.11 -9.92%
on 07/06/26
+3.47 (+37.55%)
since 06/10/26
3-Month
7.15 +77.76%
on 04/29/26
14.11 -9.92%
on 07/06/26
+5.42 (+74.35%)
since 04/10/26
52-Week
2.87 +342.86%
on 07/31/25
14.11 -9.92%
on 07/06/26
+9.56 (+303.49%)
since 07/10/25

Most Recent Stories

More News
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

- First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world’s...

DRTS : 12.71 (-2.08%)
DRTSW : 3.66 (-5.18%)
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control

- Following the pre-specified interim safety report and overwhelming demand from clinicians to treat patients as quickly as possible, Alpha Tau to resume recruitment immediately for the remaining seven...

DRTS : 12.71 (-2.08%)
DRTSW : 3.66 (-5.18%)
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients

- Joint partnership leverages Alpha Tau’s highly potent, localized alpha-radiation technology and Tolmar’s commercial leadership to transform the U.S. uro-oncology landscape  - Collaboration...

DRTS : 12.71 (-2.08%)
DRTSW : 3.66 (-5.18%)
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting

- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of...

DRTS : 12.71 (-2.08%)
DRTSW : 3.66 (-5.18%)
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears

Alpha Tau Medical (NASDAQ:DRTS) outlined a series of clinical and regulatory updates during the Lytham Partners Spring 2026 Investor Conference, with Raphi Levy of Alpha Tau telling investors the company’s...

DRTS : 12.71 (-2.08%)
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion...

DRTS : 12.71 (-2.08%)
DRTSW : 3.66 (-5.18%)
Alpha Tau to Participate in May Investor Conferences

JERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT...

DRTS : 12.71 (-2.08%)
DRTSW : 3.66 (-5.18%)
Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...

DRTS : 12.71 (-2.08%)
Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...

DRTS : 12.71 (-2.08%)
Can Alpha Tau Medical Answer What Happens When Trial Data Arrives Before Revenue Does?

Barchart Research What to Expect from DRTS Earnings DRTS Generated May 15, 2026 Current Price $10.36 EPS Estimate $$-0.13 Consensus Rating Moderate Buy Average Move 4.28% Can Alpha Tau Medical Answer What...

DRTS : 12.71 (-2.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alpha Tau Medical Ltd. is a medical device company. It focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. Alpha Tau Medical Ltd., formerly known as Healthcare Capital Corp., is based in JERUSALEM.

See More

Key Turning Points

3rd Resistance Point 14.79
2nd Resistance Point 14.10
1st Resistance Point 13.40
Last Price 12.71
1st Support Level 12.01
2nd Support Level 11.32
3rd Support Level 10.62

See More

52-Week High 14.11
Last Price 12.71
Fibonacci 61.8% 9.82
Fibonacci 50% 8.49
Fibonacci 38.2% 7.16
52-Week Low 2.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.